Emerald Mutual Fund Advisers Trust Amylyx Pharmaceuticals, Inc. Transaction History

Emerald Mutual Fund Advisers Trust

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 05, 2024	SELL	$12.07 - $18.46 $299,094 - $457,438	-24,780 Reduced 3.64%	656,530 $9.66 Million
Q3 2023 Oct 26, 2023	BUY	$18.08 - $23.45 $23,051 - $29,898	1,275 Added 0.19%	681,310 $12.5 Million
Q2 2023 Aug 10, 2023	SELL	$20.98 - $31.42 $2.3 Million - $3.44 Million	-109,556 Reduced 13.88%	680,035 $14.7 Million
Q1 2023 May 04, 2023	BUY	$27.71 - $40.93 $3.73 Million - $5.51 Million	134,576 Added 20.55%	789,591 $23.2 Million
Q4 2022 Feb 03, 2023	BUY	$29.75 - $39.26 $5.45 Million - $7.19 Million	183,128 Added 38.81%	655,015 $24.2 Million
Q3 2022 Oct 25, 2022	BUY	$17.15 - $30.92 $8.09 Million - $14.6 Million	471,887 New	471,887 $13.3 Million

139

46.5M

226K

909K

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $290M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

Get notified when there are updates to the investment portfolio of Emerald Mutual Fund Advisers Trust, based on Form 13F filings with the SEC.

Stay updated on Emerald Mutual Fund Advisers Trust with notifications on news.